Trending Topic

virus closeup, contagious pathogen. Monkey pox virus closeup, contagious pathogen, infectious zoonotic disease
7 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

A double-stranded DNA virus of the Orthopoxvirus family, mpox (formerly monkeypox), continues to infect people daily, following the 2022 global outbreak.1 Two clades (clade 1 and clade 2) have been identified, with the 2022 outbreak caused by a subclade of clade 2, referred to as clade 2b.2 Comparatively, clade 1 leads to a more severe disease state and greater […]

11 mins

Moti Ramgopal, IDWeek 2022: Phase 3/3b FLAIR and ATLAS-2M pooled analysis – Efficacy and safety outcomes through week 96 by race

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 25th 2022

Long-acting cabotegravir + rilpivirine administered monthly or every 2 months is the first and only complete long-acting regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression. In this touchINFECTIOUS DISEASES interview, we met with Prof. Moti Ramgopal (Midway Research Center, FL, USA) to discuss a post hoc analysis of pooled outcomes for participants in the FLAIR and ATLAS-2M global Phase 3/3b studies through Week 96 stratified by race. Dr Ramgopal discusses the efficacy and safety findings from the phase 3/3b studies, the objectives of the post-hoc analysis, and the findings in terms of safety and treatment satisfaction.

The abstract entitled: ‘Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy and Safety Outcomes Through Week 96 by Race was presented at IDWeek 2022, 19-23 October 2022.

Access an interview with Prof. Moti Ramgopal on the unmet needs and challenges around maintenance of HIV-1 virologic suppression

Questions:

  1. What did the FLAIR and ATLAS-2M teach us about the efficacy and safety of long-acting cabotegravir and rilpivirine in this treatment setting? (0:08)
  2. What was the objective of the post-hoc analysis you are presenting? (1:07)
  3. What were the findings in terms of safety and treatment satisfaction? (4:20)

Disclosures: Moti Ramgopal is a consultant for Merck, ViiV, and Gilead; and is a speaker’s bureau participant with Abbvie, Gilead, ViiV, and Janssen.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of IDWeek 2022

Access more HIV content here

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup